Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of AK112 in Combination Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC)

NCT06530251 is registered in ClinicalTrials.gov with Akeso as lead sponsor.

NCT NCT06530251
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06530251 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of AK112 in Combination Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC)
Lead sponsor
Akeso
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 24, 2024
Completion date
September 30, 2028
Enrollment
280 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma